CSIMarket
 
Repligen Corp  (RGEN)
Other Ticker:  
 
 
Price: $189.9300 $-3.65 -1.886%
Day's High: $194.46 Week Perf: -1.66 %
Day's Low: $ 189.44 30 Day Perf: -7.82 %
Volume (M): 602 52 Wk High: $ 211.13
Volume (M$): $ 114,281 52 Wk Avg: $166.46
Open: $192.22 52 Wk Low: $110.45



 Market Capitalization (Millions $) 10,786
 Shares Outstanding (Millions) 57
 Employees 1,170
 Revenues (TTM) (Millions $) 670
 Net Income (TTM) (Millions $) 116
 Cash Flow (TTM) (Millions $) 107
 Capital Exp. (TTM) (Millions $) 28

Repligen Corp
Repligen Corp is a biotechnology company that specializes in the manufacture and supply of bioprocessing products and technologies.
The company's product portfolio includes Protein A and G ligands, affinity chromatography resins, growth factor supplements for cell culture, and filtration products for virus and gene therapy production.
Repligen Corp was founded in 1981 and is headquartered in Waltham, Massachusetts.
The company's manufacturing facilities are located in Waltham, Massachusetts and Lund, Sweden.
Repligen Corp serves customers in the biopharmaceutical and biotechnology industries worldwide.
The company has a strong focus on the development of novel and innovative technologies that enhance productivity and efficiency in bioprocessing.
This has led to the creation of several proprietary technologies such as the OPUS pre-packed chromatography columns and the ATF (Alternating Tangential Flow) system for high-density cell culture perfusion.
One of Repligen Corp's key strengths is its ability to meet the stringent quality standards of the bioprocessing industry.
The company is ISO 9001:2015 certified and adheres to Good Manufacturing Practices (GMP) and Good Laboratory Practices (GLP) guidelines.
Overall, Repligen Corp is an established player in the bioprocessing industry with a strong track record of innovation and quality.
The company's focus on the development of new products and technologies that increase the efficiency and productivity of bioprocessing is expected to position it for continued growth and success in the future.


   Company Address: 41 Seyon Street, Bldg. 1, Suite 100 Waltham 2453 MA
   Company Phone Number: 250-0111   Stock Exchange / Ticker: NASDAQ RGEN
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Financing Agreement

Repligen's Private Convertible Transaction Marks a $600 Million Milestone, Strengthening Financial Position and Driving Growth

Published Thu, Dec 7 2023 12:30 PM UTC

Repligen Corporation, a leading biotechnology and pharmaceutical company, has recently made a significant announcement regarding a private convertible transaction. On December 6, 2023, Repligen entered into privately negotiated exchange and subscription agreements with specific holders of its outstanding 0.375% Convertible Senior Notes due 2024 (the 2024 Notes) as well as ne...

Repligen Corp

Repligen Corp: Earnings Bolstered by $6.54 Million Tax Provisions Amid Slumping Profits



Repligen Corp, a prominent player in the Biotechnology & Pharmaceuticals industry, recently released its financial results for the July to September 30, 2023, reporting period. The results indicate a significant slump in net profit per share and revenue, contrasting with the industry's overall positive trend. This article aims to provide a comprehensive analysis of Repligen Corp's financial performance and its implications.
Financial Snapshot:
For the July to September 30, 2023 financial period, Repligen Corp experienced a notable decline in net profit per share. It dropped by 54.93% to $0.32 per share, compared to $0.71 per share in the same period the previous year. Additionally, net profit per share decreased by 8.57% from the preceding reporting period, falling from $0.35 per share.

Repligen Corp

Repligen Corp Reports Significant Revenue Drop of 23.341% and Income Slump by 60.23% in Q2 2023, Falling Behind Biotech & Pharmaceuticals Sector

Revenue Demise Causes Slump in Income for Repligen Corp in Q2 2023
By [Author Name]
Investors were taken aback when Repligen Corp reported a significant decline in revenue for the second quarter of the 2023 earnings season, resulting in a slump in income. The company's revenue plummeted by a staggering -23.341%, dropping to $159.17 million from $207.63 million in the same period the previous year. This decline in revenue is in stark contrast to the overall growth seen in the Biotechnology & Pharmaceuticals sector.
The company also witnessed a decline in earnings per share (EPS), with only $0.35 per share recorded for Q2 2023 compared to $0.88 per share in the prior year. The drop in EPS further intensified concerns among investors.

Repligen Corp

Very difficult fiscal period at Repligen Corp in the financial first quarter of 2023

Repligen Corp, a well-known Biotechnology and Pharmaceuticals company, has recently reported an 8.96% return on equity (ROE) for its first quarter in 2023. This figure is higher than RGEN's average ROE of 6.61%, which is a good sign. However, there are seven other companies in the same industry that have higher ROEs than Repligen Corp.
Although the company's overall ranking for ROE has improved in the first quarter of 2023, falling net income resulted in a reduction in ROE compared to the previous period. Repligen Corp has shown a market trend of declining income, with a -11.502% drop in revenue and a -37.04% decrease in income per share in the first quarter of 2023, year on year. The company's revenue fell to $182.66 million, from $206.40 million in the same period last year, while earnings per share were $0.51, compared to $0.81 a year earlier.






 

Repligen's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com